Form 4: Exelixis CEO Michael Morrissey Reports Stock Award and Holdings

Michael Morrissey, CEO of Exelixis, reports the acquisition of performance-based restricted stock units and holdings in common stock through various means, including a family trust and a 401(k) plan.

Summary

• Michael Morrissey, the President and CEO of Exelixis, filed a Form 4 detailing changes in his beneficial ownership of Exelixis stock.
• On March 31, 2025, Morrissey was granted 589,719 performance-based restricted stock units (PSUs) under the 2017 Equity Incentive Plan.
• These PSUs will vest if the volume-weighted average closing price of Exelixis common stock equals or exceeds $60 for 90 consecutive calendar days within a five-year period, and if Morrissey remains employed through the fifth anniversary of the grant date.
• Morrissey also holds 1,623,009 shares of common stock that will be issued upon the vesting of restricted stock units (RSUs) and PSUs.
• He also has 1,764,985 shares held in the Morrissey Family Living Trust and 17,728 shares in the Exelixis, Inc. 401(k) Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock ownership changes. The PSU award is a positive incentive for the CEO, but the filing itself is factual.

Positives

• The granting of performance-based restricted stock units incentivizes the CEO to drive the company's stock price higher.
• The vesting conditions tied to both stock price and continued employment align the CEO's interests with those of the shareholders.

Risks

• The performance-based vesting condition may not be met if the stock price does not reach the $60 target.
• The service-based vesting condition could be impacted by unforeseen circumstances affecting Morrissey's employment.

Future Outlook

The document does not contain specific forward-looking statements, but the PSU award suggests an expectation of future stock price appreciation.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Equity compensation packages, including PSUs and RSUs, are common among publicly traded biotechnology companies like Exelixis to incentivize executives.
• Vesting conditions tied to stock price performance are also typical, aligning executive compensation with shareholder value creation.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The PSU award aligns the CEO's interests with shareholders, potentially driving long-term value creation.
• Transparency in stock ownership changes provides stakeholders with insights into management's commitment to the company.

Key Dates

Keywords

Exelixis, Michael Morrissey, Form 4, Beneficial Ownership, Stock Options, PSU, RSU, Equity Incentive Plan, Securities, CEO